A proneurogenic, neuroprotective chemical that preserves newly created brain cells and boosts learning and memory in animal studies. The discovery could have implications for developing treatments of neuropsychiatric and neurodegenerative diseases. These include schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, and abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine, and cocaine.
A rifamycin-quinolone hybrid antibiotic that represents a unique agent for the treatment of a variety of infections that are recalcitrant to current antibiotic therapy. CBR-2092 combines the rifamycin SV pharmacophore with a quinolone pharmacophore derived from the 4H-4-oxoquinolizine (or “2-pyridone”) subfamily of so-called fourth generation fluoroquinolones, resulting in an agent that combines the critical antimicrobial properties of both parent molecules while overcoming their individual resistance development liabilities. Initial in-human studies have shown that CBR-2092 is generally safe and well-tolerated. It is anticipated that CBR-2092 will be efficacious against a broad variety of infections, including medical device/implant-related biofilm infections and MRSA, MRSE, VISA, GISA and MDR staphylococci & streptococci.
2M BioTech partners with research groups, universities, inventors, and early stage biotech firms to accelerate the commercialization of their products and technologies. 2M BioTech provides an alternative to the traditional models associated with university-based technology licensing offices and venture capital financing.